X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Natco Pharma Fact Sheet, Natco Pharma Financial Results - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

Natco Pharma Fact Sheet   (NTPH)

Here is the latest financial fact sheet of Natco Pharma. For more details, see the Natco Pharma quarterly results and Natco Pharma share price and chart. For a sector overview, read our pharmaceuticals sector report.

NATCO PHARMA Price History

Price Rs 800.0
Mkt Cap Rs m 132,912
Vol '000 39.7
P/E X 36.0
P/CF X 103.4
EPS (TTM) Rs 22.2
% ch % -0.6
No. of shares m 166.15
% ch week % -0.6
% ch 1-mth % 9.1
% ch 12-mth % 26.5
52 week H/L Rs 1,080.0/495.0
(As on Sep 22, 2017 (Close))
* Results Consolidated
Excel EXPORT | DO YOU LIKE THESE FACTSHEETS? TELL US!

NATCO PHARMA Financials

No. of Mths
Year Ending
12
Mar-10
*
12
Mar-11
*
12
Mar-12
*
12
Mar-13
*
12
Mar-14
*
5-Yr Chart
Click to enlarge
NATCO PHARMA EQUITY SHARE DATA
High Rs156358361505877 
Low Rs47134197330424 
Sales per share (Unadj.) Rs162.2163.3168.1210.6223.4 
Earnings per share (Unadj.) Rs17.319.019.122.931.1 
Diluted earnings per shareRs2.93.23.64.36.2 
Cash flow per share (Unadj.) Rs24.324.724.230.040.3 
Dividends per share (Unadj.) Rs2.002.003.004.005.00 
Adj. dividends per shareRs0.340.340.560.761.00 
Dividend yield (eoy) %2.00.81.11.00.8 
Book value per share (Unadj.) Rs108.6125.2152.0170.1219.5 
Adj. book value per shareRs18.421.228.532.143.7 
Shares outstanding (eoy) m28.1528.1531.1531.3733.07 
Bonus/Rights/Conversions  ESOP-PPESOPPA 
Price / Sales ratio x0.61.51.72.02.9 
Avg P/E ratio x5.912.914.618.220.9 
P/CF ratio (eoy) x4.210.011.513.916.1 
Price / Book Value ratio x0.92.01.82.53.0 
Dividend payout %11.610.515.717.516.1 
Avg Mkt Cap Rs m2,8576,9258,69113,10021,504 
No. of employees `000NANANANANA 
Total wages/salary Rs m5896648011,0231,128 
Avg. sales/employee Rs ThNMNMNMNMNM 
Avg. wages/employee Rs ThNMNMNMNMNM 
Avg. net profit/employee Rs ThNMNMNMNMNM 
NATCO PHARMA INCOME DATA
Net Sales Rs m4,5674,5975,2376,6057,389 
Other income Rs m464691124167 
Total revenues Rs m4,6134,6435,3296,7297,556 
Gross profit Rs m9138891,0941,4991,793 
Depreciation Rs m197159159221304 
Interest Rs m130125230263366 
Profit before tax Rs m6326517951,1391,290 
Minority Interest Rs m816116046 
Prior Period Items Rs m-160000 
Extraordinary Inc (Exp) Rs m000-1160 
Tax Rs m137132211364309 
Profit after tax Rs m4875355967191,027 
Gross profit margin %20.019.320.922.724.3 
Effective tax rate %21.620.326.532.023.9 
Net profit margin %10.711.611.410.913.9 
NATCO PHARMA BALANCE SHEET DATA
Current assets Rs m1,9232,4702,9283,3053,681 
Current liabilities Rs m1,6461,9342,5943,4493,123 
Net working cap to sales %6.111.76.4-2.27.6 
Current ratio x1.21.31.11.01.2 
Inventory Days Days6281778189 
Debtors Days Days4656667259 
Net fixed assets Rs m3,0143,4614,8406,8867,685 
Share capital Rs m282282312314331 
"Free" reserves Rs m2,5363,0054,1384,7686,670 
Net worth Rs m3,0573,5244,7365,3357,259 
Long term debt Rs m5221,2541,3411,378955 
Total assets Rs m5,5437,0739,05210,80411,957 
Interest coverage x5.86.24.55.34.5 
Debt to equity ratio x0.20.40.30.30.1 
Sales to assets ratio x0.80.60.60.60.6 
Return on assets %11.19.39.19.111.7 
Return on equity %15.915.212.613.514.2 
Return on capital %21.116.617.120.120.7 
Exports to sales %21.128.334.242.739.4 
Imports to sales %4.17.07.47.45.7 
Exports (fob) Rs m9641,3011,7902,8172,908 
Imports (cif) Rs m187323388486421 
Fx inflow Rs m9821,3992,1783,2053,445 
Fx outflow Rs m209446570628703 
Net fx Rs m7749531,6082,5772,743 
NATCO PHARMA CASH FLOW
From Operations Rs m 774 370 649 612 1,440 
From Investments Rs m -609 -888 -1,269 -1,071 -1,089 
From Financial Activity Rs m -342 771 628 263 -353 
Net Cashflow Rs m -176 253 8 -196 -1 
* Results Consolidated
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Share Holding

Indian Promoters 52.0%
Foreign collaborators 1.5%
Indian inst/Mut Fund 7.8%
FIIs 16.6%
ADR/GDR 0.0%
Free float 26.0%
Shareholders 25,395
Pledged promoter(s) holding 0.0%
 

Company Information

REGD OFF NATCO House, Road No.2, Banjara Hills, Hyderabad - 500 033
E-MAIL investors@natcopharma.co.in WEB www.natcopharma.co.in
TELEPHONE (040) 2354 7532 FAX (040) 2354 8243
SECTOR PHARMACEUTICALS GROUP MISCELLANEOUS
TR AGENT Venture Capital, 12-10-167, Bharatnagar, Hyderabad-500 018
AUDITOR Walker, Chandiok & Co.
CHM: V. C. Nannapaneni (MD) COMP SEC: M. Adinarayana YEAR OF INC: 1981 BSE CODE: 524816 FV (Rs): 10 DIV YIELD (%): 0.1

More Pharmaceuticals Company Fact Sheets:   FDC LTD.  DISHMAN PHARMA  ALEMBIC LTD  INDOCO REMEDIES  J.B.CHEMICALS  

Compare NATCO PHARMA With:   FDC LTD.  DISHMAN PHARMA  ALEMBIC LTD  INDOCO REMEDIES  J.B.CHEMICALS  

Compare NATCO PHARMA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Steady Despite North Korea Threat(RoundUp)

Global financial markets ended the week on a flat note despite North Korea once again threatening to test a hydrogen bomb in the Pacific Ocean.

Views on news

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

More Views on News

Most Popular

India's Big and Messy Real Estate Ponzi Scheme, Just Got Messier(Vivek Kaul's Diary)

Sep 11, 2017

The question is, whether real estate buyers are financial creditors or not.

Feeling Left Out? Two Opportunities to Make Money in This Market(Daily Profit Hunter)

Sep 13, 2017

Nifty is above 10,000 once again. Have you missed the bus?

Rule-Based Investing Can Make A Lot of Money(The 5 Minute Wrapup)

Sep 16, 2017

We take a glimpse of Equitymaster's results from rule based investing.

Introducing Smart Contrarian: The Blueprint for Big Profits from Small Investments

Sep 18, 2017

Welcome to a bold, new initiative designed for the truly contrarian investor.

How To Link Aadhaar With Your Mutual Fund Investments(Outside View)

Sep 11, 2017

The Government has extended the linking of the unique Aadhaar number to nearly all financial transactions.

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON NATCO PHARMA

NATCO PHARMA - MYLAN COMPARISON

COMPARE NATCO PHARMA WITH

MARKET STATS